Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Archives of Dermatological Research
Published in: Archives of Dermatological Research 2/2019

01-03-2019 | Review

The role of PI3K/AKT/FOXO signaling in psoriasis

Authors: Miao Zhang, Xiaoyan Zhang

Published in: Archives of Dermatological Research | Issue 2/2019

Login to get access

Abstract

Phosphatidylinositol 3-kinase (PI3K) and protein kinase B (AKT) signaling pathway play a central role in multiple cellular functions such as cell proliferation and survival. The forkhead box O (FOXO) transcription factors are negatively regulated by the PI3K/AKT signaling pathway and considered to have inhibitory effect on cell proliferation. Psoriasis is a multifactorial disease with a strong genetic background and characterized by hyperproliferative keratinocyte. PI3K signaling regulates proliferation of keratinocyte by activating AKT and other targets, and by inducing FOXO downregulation. The amplification of PI3K and AKT and the loss of the FOXO are gradually being recognized in psoriatic lesions. The upstream and downstream of PI3K/AKT signaling molecules such as tumor suppressor phosphatase and tensin homolog (PTEN) and mammalian target of Rapamycin (mTOR), respectively, are also frequently altered in psoriasis. In this review, we highlight the recent studies on the roles and mechanisms of PI3K and AKT in regulating hyperproliferation of keratinocyte, and the roles of the downstream targets FOXO in psoriasis. Finally, we summarized that PI3K/AKT/FOXO signaling and its upstream and downstream molecule which could be underlying therapeutic target for psoriasis. This article is part of a special issue entitled: PI3K–AKT–FOXO axis in psoriasis.
Literature
1.
Aksamitiene E, Kiyatkin A, Kholodenko BN (2012) Cross-talk between mitogenic Ras/MAPK and survival PI3K/Akt pathways: a fine balance. Biochem Soc Trans 40:139–146CrossRefPubMed
2.
Aktas B, Tewes M, Fehm T, Hauch S, Kimmig R et al (2009) Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients. Breast Cancer Res 11:R46CrossRefPubMedPubMedCentral
3.
Albert V, Hall MN (2015) mTOR signaling in cellular and organismal energetics. Curr Opin Cell Biol 33:55–66CrossRefPubMed
4.
Amin AG, Wang A, Braun A, Tobias M, Murali R et al (2017) Abstract 3125: Therapeutic implications of mTORC1 and mTORC2 inhibitors in genetically heterogeneous glioblastoma. Can Res 77:3125–3125CrossRef
5.
Balato A, Caprio RD, Lembo S, Mattii M, Megna M et al (2014) Mammalian target of rapamycin in inflammatory skin conditions. Eur J Inflamm 12:341–350CrossRef
6.
Balato A, Lembo S, Ayala F, Balato N, Caiazzo G et al (2017) Mechanistic target of rapamycin complex 1 is involved in psoriasis and regulated by anti-TNF-alpha treatment. Exp Dermatol 26:325–327CrossRefPubMed
7.
Bao S, Ouyang G, Bai X, Huang Z, Ma C et al (2004) Periostin potently promotes metastatic growth of colon cancer by augmenting cell survival via the Akt/PKB pathway. Cancer Cell 5:329–339CrossRefPubMed
8.
Birkenkamp KU, Coffer PJ (2003) Regulation of cell survival and proliferation by the FOXO (Forkhead box, class O) subfamily of Forkhead transcription factors. Biochem Soc Trans 31:292–297CrossRefPubMed
9.
Bradley AW, James ED, Charles JM (2011) New organ-specific pharmacological strategies interfering with signaling pathways in inflammatory disorders/autoimmune disorders. Curr Signal Transduct Ther 6:279–291CrossRef
10.
Brazil DP, Hemmings BA (2001) Ten years of protein kinase B signalling: a hard Akt to follow. Trends Biochem Sci 26:657–664CrossRefPubMed
11.
Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P et al (1999) Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96:857–868CrossRefPubMed
12.
Brunet A, Kanai F, Stehn J, Xu J, Sarbassova D et al (2002) 14-3-3 transits to the nucleus and participates in dynamic nucleocytoplasmic transport. J Cell Biol 156:817–828CrossRefPubMedPubMedCentral
13.
Buerger C, Malisiewicz B, Eiser A, Hardt K, Boehncke WH (2013) Mammalian target of rapamycin and its downstream signalling components are activated in psoriatic skin. Br J Dermatol 169:156–159CrossRefPubMed
14.
Buerger C, Shirsath N, Lang V, Berard A, Diehl S et al (2017) Inflammation dependent mTORC1 signaling interferes with the switch from keratinocyte proliferation to differentiation. PLoS One 12:e0180853CrossRefPubMedPubMedCentral
15.
Burger C, Shirsath N, Lang V, Diehl S, Kaufmann R et al (2017) Blocking mTOR Signalling with Rapamycin ameliorates Imiquimod-induced Psoriasis in Mice. Acta Derm Venereol 97:1087–1094CrossRefPubMed
16.
17.
Burgering BM, Kops GJ (2002) Cell cycle and death control: long live Forkheads. Trends Biochem Sci 27:352–360CrossRefPubMed
18.
Burgering BM, Medema RH (2003) Decisions on life and death: FOXO Forkhead transcription factors are in command when PKB/Akt is off duty. J Leukoc Biol 73:689–701CrossRefPubMed
19.
Calautti E, Li J, Saoncella S, Brissette JL, Goetinck PF (2005) Phosphoinositide 3-kinase signaling to Akt promotes keratinocyte differentiation versus death. J Biol Chem 280:32856–32865CrossRefPubMed
20.
21.
22.
23.
Chamcheu JC, Adhami VM, Esnault S, Sechi M, Siddiqui IA et al (2017) Dual Inhibition of PI3K/Akt and mTOR by the dietary antioxidant, delphinidin, ameliorates psoriatic features in vitro and in an imiquimod-induced psoriasis-like disease in mice. Antioxid Redox Signal 26:49–69CrossRefPubMedPubMedCentral
24.
Chamcheu JC, Chaves-Rodriquez MI, Adhami VM, Siddiqui IA, Wood GS et al (2016) Upregulation of PI3K/AKT/mTOR, FABP5 and PPARbeta/delta in human psoriasis and imiquimod-induced murine psoriasiform dermatitis model. Acta Derm Venereol 96:854–856PubMedPubMedCentral
25.
Chamcheu JC, Pal HC, Siddiqui IA, Adhami VM, Ayehunie S et al (2015) Prodifferentiation, anti-inflammatory and antiproliferative effects of delphinidin, a dietary anthocyanidin, in a full-thickness three-dimensional reconstituted human skin model of psoriasis. Skin Pharmacol Physiol 28:177–188CrossRefPubMed
26.
Chen L, Wu J, Pier E, Zhao Y, Shen Z (2013) mTORC2-PKBalpha/Akt1 Serine 473 phosphorylation axis is essential for regulation of FOXP3 stability by chemokine CCL3 in psoriasis. J Invest Dermatol 133:418–428CrossRefPubMed
27.
Chen SJ, Nakahara T, Takahara M, Kido M, Dugu L et al (2009) Activation of the mammalian target of rapamycin signalling pathway in epidermal tumours and its correlation with cyclin-dependent kinase 2. Br J Dermatol 160:442–445CrossRefPubMed
28.
Christophers E (2001) Psoriasis–epidemiology and clinical spectrum. Clin Exp Dermatol 26:314–320CrossRefPubMed
29.
Coffre M, Benhamou D, Riess D, Blumenberg L, Snetkova V et al (2016) miRNAs are essential for the regulation of the PI3K/AKT/FOXO pathway and receptor editing during B cell maturation. Cell Rep 17:2271–2285CrossRefPubMedPubMedCentral
30.
Datta Mitra A, Raychaudhuri SP, Abria CJ, Mitra A, Wright R et al (2013) 1alpha,25-Dihydroxyvitamin-D3-3-bromoacetate regulates AKT/mTOR signaling cascades: a therapeutic agent for psoriasis. J Invest Dermatol 133:1556–1564CrossRefPubMed
31.
Deane JA, Fruman DA (2004) Phosphoinositide 3-kinase: diverse roles in immune cell activation. Annu Rev Immunol 22:563–598CrossRefPubMed
32.
Diehl JA, Cheng M, Roussel MF, Sherr CJ (1998) Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev 12:3499–3511CrossRefPubMedPubMedCentral
33.
Ding X, Bloch W, Iden S, Ruegg MA, Hall MN et al (2016) mTORC1 and mTORC2 regulate skin morphogenesis and epidermal barrier formation. Nat Commun 7:13226CrossRefPubMedPubMedCentral
34.
Downward J (1998) Mechanisms and consequences of activation of protein kinase B/Akt. Curr Opin Cell Biol 10:262–267CrossRefPubMed
35.
Eijkelenboom A, Burgering BM (2013) FOXOs: signalling integrators for homeostasis maintenance. Nat Rev Mol Cell Biol 14:83–97CrossRefPubMed
36.
Engelman JA, Luo J, Cantley LC (2006) The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 7:606–619CrossRefPubMed
37.
Essafi A, Gomes AR, Pomeranz KM, Zwolinska AK, Varshochi R et al (2009) Studying the subcellular localization and DNA-binding activity of FoxO transcription factors, downstream effectors of PI3K/Akt. Methods Mol Biol 462:201–211PubMed
38.
Faivre S, Kroemer G, Raymond E (2006) Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 5:671–688CrossRefPubMed
39.
Florek AG, Wang CJ, Armstrong AW (2018) Treatment preferences and treatment satisfaction among psoriasis patients: a systematic review. Arch Dermatol Res 310:271–319CrossRefPubMed
40.
Frigerio E, Colombo MD, Franchi C, Altomare A, Garutti C et al (2007) Severe psoriasis treated with a new macrolide: everolimus. Br J Dermatol 156:372–374CrossRefPubMed
41.
42.
43.
Gonzalez E, McGraw TE (2009) The Akt kinases: isoform specificity in metabolism and cancer. Cell Cycle 8:2502–2508CrossRefPubMed
44.
Greer EL, Brunet A (2005) FOXO transcription factors at the interface between longevity and tumor suppression. Oncogene 24:7410–7425CrossRefPubMed
45.
Guo S, Rena G, Cichy S, He X, Cohen P et al (1999) Phosphorylation of serine 256 by protein kinase B disrupts transactivation by FKHR and mediates effects of insulin on insulin-like growth factor-binding protein-1 promoter activity through a conserved insulin response sequence. J Biol Chem 274:17184–17192CrossRefPubMed
46.
Gupta D, Syed NA, Roesler WJ, Khandelwal RL (2004) Effect of overexpression and nuclear translocation of constitutively active PKB-alpha on cellular survival and proliferation in HepG2 cells. J Cell Biochem 93:513–525CrossRefPubMed
47.
Gutknecht M, Schaarschmidt ML, Danner M, Otten M, Augustin M (2018) How to weight patient-relevant treatment goals for assessing treatment benefit in psoriasis: preference elicitation methods vs. rating scales. Arch Dermatol Res 310(8):1–11
48.
Hambly R, Kirby B (2017) The relevance of serum vitamin D in psoriasis: a review. Arch Dermatol Res 309:499–517CrossRefPubMed
49.
50.
Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB (2005) Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 4:988–1004CrossRefPubMed
51.
Hong KK, Gwak MJ, Song J, Kim NI (2016) Nuclear factor-kappaB pathway activation and phosphatase and tensin homolog downregulation in psoriasis. Br J Dermatol 174:433–435CrossRefPubMed
52.
Hresko RC, Murata H, Mueckler M (2003) Phosphoinositide-dependent kinase-2 is a distinct protein kinase enriched in a novel cytoskeletal fraction associated with adipocyte plasma membranes. J Biol Chem 278:21615–21622CrossRefPubMed
53.
Huang L, Xue R (2014) The expressions of p-Akt and p-FoxO1 in the lesions of psoriasis vulgaris (in Chinese). Chin J Leprosy Skin Dis 30:737–739
54.
Huang T, Lin X, Meng X, Lin M (2014) Phosphoinositide-3 kinase/protein kinase-B/mammalian target of rapamycin pathway in psoriasis pathogenesis. A potential therapeutic target? Acta Derm Venereol 94:371–379CrossRefPubMed
55.
Imai-Sumida M, Chiyomaru T, Majid S, Saini S, Nip H et al (2017) Silibinin suppresses bladder cancer through down-regulation of actin cytoskeleton and PI3K/Akt signaling pathways. Oncotarget 8:92032–92042CrossRefPubMedPubMedCentral
56.
Irie HY, Pearline RV, Grueneberg D, Hsia M, Ravichandran P et al (2005) Distinct roles of Akt1 and Akt2 in regulating cell migration and epithelial-mesenchymal transition. J Cell Biol 171:1023–1034CrossRefPubMedPubMedCentral
57.
58.
Kaestner KH, Knochel W, Martinez DE (2000) Unified nomenclature for the winged helix/forkhead transcription factors. Genes Dev 14:142–146PubMed
59.
60.
Kops GJ, Burgering BM (2000) Forkhead transcription factors are targets of signalling by the proto-oncogene PKB (C-AKT). J Anat 197 Pt 4:571–574CrossRef
61.
Kops GJ, Burgering BM (1999) Forkhead transcription factors: new insights into protein kinase B (c-akt) signaling. J Mol Med (Berl) 77:656–665CrossRef
62.
Kops GJ, de Ruiter ND, De Vries-Smits AM, Powell DR, Bos JL et al (1999) Direct control of the Forkhead transcription factor AFX by protein kinase B. Nature 398:630–634CrossRefPubMed
63.
64.
Li J, Yen C, Liaw D, Podsypanina K, Bose S et al (1997) PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275:1943–1947CrossRefPubMed
65.
Li Q, Huang H, He Z, Sun Y, Tang Y et al (2018) Regulatory effects of antitumor agent matrine on FOXO and PI3K-AKT pathway in castration-resistant prostate cancer cells. Sci China Life Sci 61:550–558CrossRefPubMed
66.
Li Y, Man X, You L, Xiang Q, Li H et al (2014) Downregulation of PTEN expression in psoriatic lesions. Int J Dermatol 53:855–860CrossRefPubMed
67.
Lin AM, Rubin CJ, Khandpur R, Wang JY, Riblett MB et al (2011) Mast cells and neutrophils release IL-17 through extracellular trap formation in psoriasis. J Immunol 187:490–500CrossRefPubMed
68.
Liu Y, Luo W, Chen S (2011) Comparison of gene expression profiles reveals aberrant expression of FOXO1, Aurora A/B and EZH2 in lesional psoriatic skins. Mol Biol Rep 38:4219–4224CrossRefPubMed
69.
70.
Lowes MA, Bowcock AM, Krueger JG (2007) Pathogenesis and therapy of psoriasis. Nature 445:866–873CrossRefPubMed
71.
Lowes MA, Russell CB, Martin DA, Towne JE, Krueger JG (2013) The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses. Trends Immunol 34:174–181CrossRefPubMedPubMedCentral
72.
Ma J, Matkar S, He X, Hua X (2018) FOXO family in regulating cancer and metabolism. Semin Cancer Biol 50:32–41CrossRefPubMed
73.
Madonna S, Scarponi C, Pallotta S, Cavani A, Albanesi C (2012) Anti-apoptotic effects of suppressor of cytokine signaling 3 and 1 in psoriasis. Cell Death Dis 3:e334CrossRefPubMedPubMedCentral
74.
75.
Maehama T, Dixon JE (1998) The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 273:13375–13378CrossRefPubMed
76.
Malemud CJ (2009) The discovery of novel experimental therapies for inflammatory arthritis. Mediat Inflamm 2009: 698769
77.
Malemud CJ (2015) The PI3K/Akt/PTEN/mTOR pathway: a fruitful target for inducing cell death in rheumatoid arthritis? Fut Med Chem 7:1137–1147CrossRef
78.
Man X, Zhang X, Li H (2011) The Expression of Akt1,Akt2,Akt3 in the lesions of Psoriasis vulgaris the Chinese (in Chinese). J Dermatovenereol 25:338–340
79.
Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A et al (2008) The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133:704–715CrossRefPubMedPubMedCentral
80.
81.
82.
Melnik BC (2013) Western diet-mediated mTORC1-signaling in Acne, psoriasis, atopic dermatitis, and related diseases of civilization: therapeutic role of plant-derived natural mTORC1 inhibitors. In: Watson R, Zibadi S (eds) Bioactive dietary factors and plant extracts in dermatology nutrition and health. Humana Press, Totowa, pp 397–419CrossRef
83.
84.
Mitra A, Raychaudhuri SK, Raychaudhuri SP (2012) IL-22 induced cell proliferation is regulated by PI3K/Akt/mTOR signaling cascade. Cytokine 60:38–42CrossRefPubMed
85.
Moeinifard M, Hassan ZM, Fallahian F, Hamzeloo-Moghadam M, Taghikhani M (2017) Britannin induces apoptosis through AKT-FOXO1 pathway in human pancreatic cancer cells. Biomed Pharmacother 94:1101–1110CrossRefPubMed
86.
Monfrecola G, Lembo S, Caiazzo G, De Vita V, Di Caprio R et al (2016) Mechanistic target of rapamycin (mTOR) expression is increased in acne patients’ skin. Exp Dermatol 25:153–155CrossRefPubMed
87.
Murayama K, Kimura T, Tarutani M, Tomooka M, Hayashi R et al (2007) Akt activation induces epidermal hyperplasia and proliferation of epidermal progenitors. Oncogene 26:4882–4888CrossRefPubMed
88.
Neshat MS, Mellinghoff IK, Tran C, Stiles B, Thomas G et al (2001) Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci USA 98:10314–10319CrossRefPubMedPubMedCentral
89.
90.
91.
O’Shaughnessy RF, Welti JC, Cooke JC, Avilion AA, Monks B et al (2007) AKT-dependent HspB1 (Hsp27) activity in epidermal differentiation. J Biol Chem 282:17297–17305CrossRefPubMed
92.
Ochaion A, Bar-Yehuda S, Cohen S, Barer F, Patoka R et al (2009) The anti-inflammatory target A(3) adenosine receptor is over-expressed in rheumatoid arthritis, psoriasis and Crohn’s disease. Cell Immunol 258:115–122CrossRefPubMed
93.
Ogg S, Paradis S, Gottlieb S, Patterson GI, Lee L et al (1997) The Fork head transcription factor DAF-16 transduces insulin-like metabolic and longevity signals in C. elegans. Nature 389:994–999CrossRefPubMed
94.
Pankow S, Bamberger C, Klippel A, Werner S (2006) Regulation of epidermal homeostasis and repair by phosphoinositide 3-kinase. J Cell Sci 119:4033–4046CrossRefPubMed
95.
Paradis S, Ruvkun G (1998) Caenorhabditis elegans Akt/PKB transduces insulin receptor-like signals from AGE-1 PI3 kinase to the DAF-16 transcription factor. Genes Dev 12:2488–2498CrossRefPubMedPubMedCentral
96.
Peng XD, Xu PZ, Chen ML, Hahn-Windgassen A, Skeen J et al (2003) Dwarfism, impaired skin development, skeletal muscle atrophy, delayed bone development, and impeded adipogenesis in mice lacking Akt1 and Akt2. Genes Dev 17:1352–1365CrossRefPubMedPubMedCentral
97.
Pike MC, Lee CS, Elder JT, Voorhees JJ, Fisher GJ (1989) Increased phosphatidylinositol kinase activity in psoriatic epidermis. J Invest Dermatol 92:791–797CrossRefPubMed
98.
Raychaudhuri SK, Raychaudhuri SP (2014) mTOR signaling cascade in psoriatic disease: double kinase mTOR inhibitor a novel therapeutic target. Indian J Dermatol 59:67–70CrossRefPubMedPubMedCentral
99.
Raychaudhuri SP, Raychaudhuri SK, Atkuri KR, Herzenberg LA, Herzenberg LA (2011) Nerve growth factor: a key local regulator in the pathogenesis of inflammatory arthritis. Arthritis Rheum 63:3243–3252CrossRefPubMed
100.
Sa SM, Valdez PA, Wu J, Jung K, Zhong F et al (2007) The effects of IL-20 subfamily cytokines on reconstituted human epidermis suggest potential roles in cutaneous innate defense and pathogenic adaptive immunity in psoriasis. J Immunol 178:2229–2240CrossRefPubMed
101.
Saoncella S, Tassone B, Deklic E, Avolio F, Jon C et al (2014) Nuclear Akt2 opposes limbal keratinocyte stem cell self-renewal by repressing a FOXO-mTORC1 signaling pathway. Stem Cells 32:754–769CrossRefPubMed
102.
Sarbassov DD, Guertin DA, Ali SM, Sabatini DM (2005) Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307:1098–1101CrossRefPubMed
103.
Saxena A, Raychaudhuri SK, Raychaudhuri SP (2011) Interleukin-17-induced proliferation of fibroblast-like synovial cells is mTOR dependent. Arthritis Rheum 63:1465–1466CrossRefPubMed
104.
Saxton RA, Sabatini DM (2017) mTOR signaling in growth, metabolism, and disease. Cell 169:361–371CrossRefPubMed
105.
Scott PH, Brunn GJ, Kohn AD, Roth RA, Lawrence JC Jr (1998) Evidence of insulin-stimulated phosphorylation and activation of the mammalian target of rapamycin mediated by a protein kinase B signaling pathway. Proc Natl Acad Sci USA 95:7772–7777CrossRefPubMedPubMedCentral
106.
Shankar S, Chen Q, Srivastava RK (2008) Inhibition of PI3K/AKT and MEK/ERK pathways act synergistically to enhance antiangiogenic effects of EGCG through activation of FOXO transcription factor. J Mol Signal 3:1–11CrossRef
107.
Shi Q, Bao S, Maxwell JA, Reese ED, Friedman HS et al (2004) Secreted protein acidic, rich in cysteine (SPARC), mediates cellular survival of gliomas through AKT activation. J Biol Chem 279:52200–52209CrossRefPubMed
108.
Shirsath N, Mayer G, Singh TP, Wolf P (2015) 8-methoxypsoralen plus UVA (PUVA) therapy normalizes signalling of phosphorylated component of mTOR pathway in psoriatic skin of K5.hTGFbeta1 transgenic mice. Exp Dermatol 24:889–891CrossRefPubMed
109.
Soares HP, Ming M, Mellon M, Young SH, Han L et al (2015) Dual PI3K/mTOR inhibitors induce rapid overactivation of the MEK/ERK Pathway in human pancreatic cancer cells through suppression of mTORC2. Mol Cancer Ther 14:1014–1023CrossRefPubMedPubMedCentral
110.
111.
Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H et al (1997) Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 15:356–362CrossRefPubMed
112.
Stokoe D, Stephens LR, Copeland T, Gaffney PR, Reese CB et al (1997) Dual role of phosphatidylinositol-3,4,5-trisphosphate in the activation of protein kinase B. Science 277:567–570CrossRefPubMed
113.
Tzivion G, Dobson M, Ramakrishnan G (2011) FoxO transcription factors; Regulation by AKT and 14-3-3 proteins. Biochim Biophys Acta 1813:1938–1945CrossRefPubMed
114.
van der Vos KE, Coffer PJ (2008) FOXO-binding partners: it takes two to tango. Oncogene 27:2289–2299CrossRefPubMed
115.
van der Vos KE, Eliasson P, Proikas-Cezanne T, Vervoort SJ, van Boxtel R et al (2012) Modulation of glutamine metabolism by the PI(3)K-PKB-FOXO network regulates autophagy. Nat Cell Biol 14:829–837CrossRefPubMed
116.
Wang H, Ran LW, Hui K, Wang XY, Zheng Y (2017) Expressions of survivin, PI3K and AKT in keratinocytes in skin lesions and their pathogenic role in psoriasis vulgaris. Nan Fang Yi Ke Da Xue Xue Bao 37:1512–1516PubMed
117.
Wang Z, Yu T, Huang P (2016) Post-translational modifications of FOXO family proteins (review). Mol Med Rep 14:4931–4941CrossRefPubMed
118.
Wendel HG, De Stanchina E, Fridman JS, Malina A, Ray S et al (2004) Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 428:332–337CrossRefPubMed
119.
Yao R, Cooper GM (1995) Requirement for phosphatidylinositol-3 kinase in the prevention of apoptosis by nerve growth factor. Science 267:2003–2006CrossRefPubMed
120.
Yuan TL, Wulf G, Burga L, Cantley LC (2011) Cell-to-cell variability in PI3K protein level regulates PI3K-AKT pathway activity in cell populations. Curr Biol 21:173–183CrossRefPubMedPubMedCentral
121.
Zhang X, Liu H, Ma S (1999) Up-regulation of phosphatidylinositol 3-kinase in psoriatic lesions. Chin Med J (Engl) 112:1097–1100
122.
Zhang X, Tang N, Hadden TJ, Rishi AK (2011) Akt, FoxO and regulation of apoptosis. Biochim Biophys Acta 1813:1978–1986CrossRefPubMed
123.
Zhang X, Zhou P, You L (2009) Increased activities of Akt in psoriatic epidermis (in Chinese). Chin J Dermatol 42:413–416
124.
Zoncu R, Efeyan A, Sabatini DM (2011) mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 12:21–35CrossRefPubMed
Metadata
Title
The role of PI3K/AKT/FOXO signaling in psoriasis
Authors
Miao Zhang
Xiaoyan Zhang
Publication date
01-03-2019
Publisher
Springer Berlin Heidelberg
Published in
Archives of Dermatological Research / Issue 2/2019
Print ISSN: 0340-3696
Electronic ISSN: 1432-069X
DOI
https://doi.org/10.1007/s00403-018-1879-8

Other articles of this Issue 2/2019

Archives of Dermatological Research 2/2019 Go to the issue

Original Paper

Downregulation of aquaporin 3 in bullous pemphigoid patients

Concise Communication

Ameliorating effect of dipotassium glycyrrhizinate on an IL-4- and IL-13-induced atopic dermatitis-like skin-equivalent model

Original Paper

Pushing and loss of elastic fibers are highly specific for melanoma and rare in melanocytic nevi

Original Paper

Ameliorative effects of green tea extract from tannase digests on house dust mite antigen-induced atopic dermatitis-like lesions in NC/Nga mice

Original Paper

Treponema pallidum induces the activation of endothelial cells via macrophage-derived exosomes